期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

不同调脂方案对经皮冠状动脉介入术后患者血脂水平和短期预后的影响 被引量：2

原文传递
导出
摘要 目的:观察他汀单用和他汀联合依折麦布对经皮冠状动脉介入(PCI)术后患者的调脂疗效和安全性以及短期预后影响。方法:将90例住院已行择期PCI的慢性稳定性心绞痛患者随机分为3组,分别给予辛伐他汀40mg/d(SI组,30例)、辛伐他汀20mg/d+依折麦布10mg/d(SI/EZ组,30例)和阿托伐他汀20mg/d(AT组,30例)治疗,随访12周。主要终点观察调脂疗效和药物不良反应及LDL-C达标率,次要终点观察3组患者PCI术后12周内主要不良心血管事件(MACE)发生率。结果:①3种调脂方案均能明显降低LDL-C、TC、TG和超敏C反应蛋白水平,同时提高HDL-C水平,且3组患者的LDL-C达标率组间比较差异无统计学意义。12周时,联合治疗组(SI/EZ组)LDL-C降低幅度(32.2%)和TG下降幅度(29.5%)均高于2个单药治疗组(SI组和AT组)(均P<0.05)。②3组均未出现有临床意义的肝酶和肌酶升高,且联合治疗组常见不良反应发生率较低。③PCI术后12周内3组MACE发生率差异无统计学意义。结论:依折麦布联合常规剂量他汀可安全用于PCI术后的调脂治疗,且疗效优于单用他汀,但未进一步降低PCI术后12周内MACE发生率。
作者 段鹏 谢英 张小勇 张西叶 刘洋
机构地区 暨南大学附属清远市人民医院胸心二区 首都医科大学附属北京安贞医院心内科 北京市理化分析测试中心
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2012年第5期398-400,共3页 Journal of Clinical Cardiology
关键词 冠心病 降血脂药 依折麦布 血管成形术 经腔 经皮冠脉动脉
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献10

  • 1SAIA F, DE FEYTER P, SERRUYS P W, et al. Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation[J]. Am J Cardiol, 2004,93 : 92-95.
  • 2MOOD G R, BAVRY A A, ROUKOZ H, et al. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention[J].Am J Cardiol, 2007, 100 : 919-923.
  • 3经皮冠状动脉介入治疗指南（2009）[J].中华心血管病杂志,2009,37(1):4-25. 被引量：546
  • 4KOTSEVA K, STAGMO M, DE BACQUER D, et al. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey[J]. Atherosclerosis, 2008,197 : 710-717.
  • 5The Collaborative Research Group for the Second Multi-center Survey of Clinical Management of Dyslipidemia in China.第二次中国临床血脂控制达标率及影响因素多中心协作研究[J].中华心血管病杂志,2007,35(5):420-427. 被引量：126
  • 6JOHNSON C, WATERS D D, DEMICCO D A, et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoe analysis of the Treating to New Targets [TNT] Study) [J]. Am J Cardiol, 2008,102 : 1312 - 1317.
  • 7BALLANTYNE C M, HOURI J, NOTARBARTOLO A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial[J].Circulation, 2003,107:2409- 2415.
  • 8PEARSON T A, LAURORA I, CHU H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemie patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals[J]. Arch Intern Med, 2000,160 : 459 -- 467.
  • 9PEARSON T A, BALLANTYNE C M, VELTRI E, et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy [ J ] . Am J Cardiol, 2009,103 : 369-374.
  • 10ASSMANNV G, KANNENBERG F, RAMEY D R, et al. Effects of ezetimihe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia [J].Curr MedRes Opin,2008,24:249--259.

二级参考文献13

  • 1CHANCE研究组.无保护左主干病变支架置入术预后及影响因素的分析——中国无保护左主干病变支架置入术注册(CHANCE)研究[J].中华心血管病杂志,2005,33(3):210-215. 被引量：19
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量：5228
  • 3武阳丰,赵冬,周北凡,王薇,李贤,刘静,李莹,孙佳艺,赵连成,吴兆苏,诸骏仁.中国成人血脂异常诊断和危险分层方案的研究[J].中华心血管病杂志,2007,35(5):428-433. 被引量：175
  • 4Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿（译）,David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志（中文版）,2007,26(3):131-139. 被引量：59
  • 5张小茜,周富荣,石济民.高效液相色谱法测血脂康胶囊及红曲中洛伐他汀的含量[J].中国中药杂志,1997,22(4):222-224. 被引量：33
  • 6Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel Ⅲ ). JAMA, 2001, 285(19) :2486-2497.
  • 7Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ guidelines. Circulation, 2004,110 ( 2 ) : 227- 239.
  • 8Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med , 2006,119(8) :676-683.
  • 9Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education Program (NCEP) Evaluation Project Utilizing Novel e-Technology (NEPTUNE) Ⅱ survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol, 2005,96(4) :556-563.
  • 10Ose L, Shah A, Davies M J, et al . Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status : results of a pooled retrospective analysis. Curr Med Res Opin, 2006, 22(5) :823-835.

共引文献670

同被引文献27

引证文献2

二级引证文献40

临床心血管病杂志
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部